(Q35609537)

9 August 2017

1 reference

title

Prostate cancer: radical prostatectomy (English)

1 reference

9 August 2017

1 reference

Joel B Nelson

1

1 reference

PubMed ID

14680309

9 August 2017

Herbert Lepor

series ordinal

2

1 reference

9 August 2017

1 November 2003

1 reference

Urologic Clinics of North America

9 August 2017

1 reference

9 August 2017

30

1 reference

9 August 2017

4

1 reference

9 August 2017

703-23, viii

1 reference

Trends in prostate cancer mortality among black men and white men in the United States

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

THE ROLE OF BLADDER NECK BIOPSY IN MEN UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY WITH PRESERVATION OF THE BLADDER NECK

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prostate specific antigen progression after radical prostatectomy in African-American men versus white men.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Identification of bone marrow micrometastases in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Needle biopsy of recurrent adenocarcinoma of the prostate after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Use of transrectal ultrasound in follow-up of postradical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Adjuvant and salvage radiotherapy after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Salvage radiotherapy for PSA failure after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Adjuvant radiation therapy for recurrent PSA after radical prostatectomy in T1-T2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Long-term effects of androgen deprivation therapy in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Evaluation and management of men whose radical prostatectomies failed: results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Early androgen deprivation for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Early hormonal therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Endothelin receptor antagonists in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Exisulind, a selective apoptotic antineoplastic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Contemporary results of anatomic radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The polycomb group protein EZH2 is involved in progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

PSA and bone scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Can Prostate-Specific Antigen Levels Predict Bone Scan Evidence of Metastases in Newly Diagnosed Prostate Cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Evaluation of preoperative ProstaScint scans in the prediction of nodal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Color Doppler imaging and transrectal sonography of the prostatic fossa after radical prostatectomy: early experience

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Salvage radiotherapy for rising or persistent PSA after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Postprostatectomy radiotherapy for high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900049-1

7 January 2021

10.1016/S0094-0143(03)00049-1

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14680309